Daring to ask “What If?”
What if, instead of merely treating disease symptoms, doctors could restore function and health by replacing tissue cells lost or damaged with disease? What if it were possible to trade daily lifelong pharmaceutical regimens for a single treatment that prevents symptoms or cures disease?
Driven by the opportunity to transform the way we treat disease, BlueRock is turning “what if” into “here’s how.” Built upon the research of the world’s foremost experts in iPSC biology and genome engineering, BlueRock is ushering in a new era of authentic cellular medicines.
The Power of cell+gene
BlueRock’s exquisite cell+gene platform takes fully differentiated adult cells, such as from blood, and returns them back to a pluripotent state – “blank canvas” cells full of potential and possibilities that can give rise to other cell types. BlueRock then forges these pluripotent cells into highly specific authentic replacements of cells that have been damaged or lost to disease. cell+gene further harnesses genetic engineering to enhance those authentic cells with specific functions to improve their therapeutic effect.
Achieving new possibilities, together
”BlueRockers” are interconnected and driven by a sense of wonder and imagination for what’s possible, and we know that the only way that we can win is by working together and learning from each other. We work every day to facilitate convergence among brilliant scientists and engineers spanning an array of disciplines – from cell biology to genetics to chemistry to medical device development to computer sciences and manufacturing – spread across three vibrant cities. The result is a stimulating interdisciplinary ecosystem with a singular focus – the relentless pursuit of an audacious goal – to transform the way we treat disease.
In our first clinical trial, BlueRock is working with leading global researchers to study the potential of cell+gene to rebuild the neural connections associated with lost motor control in patients with Parkinson’s disease (PD). The Phase 1 study of our investigational authentic cellular therapy, DA01, is evaluating its safety, tolerability and preliminary efficacy in adults with PD, and will enroll patients in the US and Canada. Click below to learn more about the study.